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Summary Transgenic mice expressing the c-myc proto-oncogene under the control of the CD2-dominant control region show stochastic
development of mainly clonal thymic lymphoma with long latency, indicating that cooperative events are needed for the development of the
fully malignant phenotype. Previous studies have suggested that T-cell receptor-associated signals can contribute to tumour development.
We have therefore used this transgenic model of T-cell transformation to determine whether antigen-specific responses could constitute an
epigenetic event in lymphomagenesis. The T-cell receptor (TcR) repertoires of lymphoma clones were analysed with a panel of monoclonal
antibodies (Abs) recognizing TcR VD chains. The V,B repertoire of tumour clones arising in these mice was non-random with over-
representation of VP8.2 TcR species. The majority of Vf8.2+ clones were of a mature CD3+ CD8 single-positive (SP) phenotype. The biased
TcR usage, together with a mature cell phenotype is consistent with the hypothesis that TcR-mediated signals cooperate with activated myc
during T-cell transformation.
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A series of events, both genetic and epigenetic, are required to
transform healthy cells to the fully malignant tumour phenotype.
While many heritable genetic changes resulting in activation of
cellularproto-oncogenes and/or inactivation oftumour-suppressor
genes have been identified, the nature and spectrum ofepigenetic
events that can contribute to the transformation process is less well
defined.
In malignancies ofmature lymphoid cells it has been suspected
that epigenetic events such as stimulation via conventional T- and
B-cell antigen receptors may contribute to tumorigenesis. Some of
the most convincing data have arisen from studies on human
follicular lymphoma. Bahler and Levy (1992) reported that muta-
tions of the immunoglobin heavy-chain variable region continued
after follicular lymphoma development, indicating an important
role for antigen in the clonal evolution of the lymphoma. Further,
the non-random nature of mutations within the variable gene
sequences of follicular lymphomas and the finding that surface
immunoglobin expression is often preserved led Zelenetz et al
(1992) to suggest that these lymphomas were subject to both posi-
tive and negative selection. The possibility that self antigens are
playing a role in the selection process is supported by the finding
that autoantibody production by follicular lymphomas is a rela-
tively frequent occurrence (Dighiero et al, 1991).
The association between H. lylori infection and gastric B-cell
lymphoma and the finding that antibiotic treatment can result in
the regression oflow-grade lymphomas (Wotherspoon et al, 1993)
have resulted in the suggestion that antigen stimulation may play a
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role in the development of these lesions. Studies carried out by
Hussell et al (1993) have indicated a role for T-cells in this
chronic, possibly autoreactive, response. Similarly, the develop-
ment ofpolyclonal plasmacytomas localized to the gut wall in E,u-
myclv-abl double transgenic mice has led to the suggestion that
tumour initiation involves stimulation by gut-associated antigen
(Harris et al, 1990; Rosenbaum et al, 1990). In agreement with
this hypothesis, antigenic stimulation has also been reported to
contribute to the plasmacytomagenesis induced by a myc/v-abl
retrovirus (Weissinger et al, 1991).
The possibility that signals mediated through the T-cell receptor
(TcR) could contribute to the transformation of lymphoid cells
arose from our studies on the pathogenesis of FeLV-induced
thymic lymphomas. During analysis of proviral integrations in
tumours, we observed one tumour with two separate retroviral
transductions. One transducing virus contained the myc oncogene,
while the other contained a processed and structurally intact TcR
5-chain (Fulton et al, 1987). This observation suggested that onco-
genic complementation between myc and the transduced TcR P-
chain may have favoured clonal outgrowth, leading us to develop a
murine model, the CD2-myc mice, to further investigate the
involvement of the TcR in myc-induced lymphomagenesis
(Cameron et al, 1996).
The CD2-myc transgenic mice develop thymic tumours exclu-
sively. The long latency, the moderate incidence and the clonal
nature of these tumours implies that in addition to myc deregula-
tion, additional events are required for tumour development.
Phenotypic examination of these tumours showed that they had
either immature CD3+CD4+CD8+ or mature CD3+CD8 SP
phenotypes. This limited phenotypic heterogeneity suggests that
thymocytes are most susceptible to myc transformation at the
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developmental stage(s) when selection events are expected. We
have previously reported that a small number of these tumours
comprised T-cells that expressed a potentially autoreactive TcR
VP chain (Cameron et al, 1996) and that such tumours were signif-
icantly associated with the mature CD3+CD8 SP phenotype. These
results suggested that negative selection or clonal anergy may be
bypassed and that endogenous antigen may generate additional
proliferative signals.
To further define the nature and extent of TcR involvement in
tumour induction/progression, we have placed the CD2-myc trans-
gene on a genetic background in which a large number ofTcR V,B
families are subjected to negative selection and examined the
tumourT-cell repertoire. Surprisingly, there was an apparent bias in
usage ofnon-deleted TcRV,8.2 in tumours that were also predom-
inantly of a mature phenotype. Considered together, these data
describe tumours comprising cells with characteristics of a mature
and antigen-restricted phenotype, suggesting the TcR may mediate
a signal(s) that can interact with myc in T-cell transformation.
MATERIALS AND METHODS
Transgenic mice
The generation of the CD2-myc transgenic mice has been
described (Stewart et al, 1993). The myc transgenic mice
(C57BL/6J and CBA/Ca mixture, hereafter referred to as
B6/CBA) were backcrossed to DBA/2 mice. The resultant F,
progeny were sacrificed when presenting with clinical signs of
tumour development, and the thymic lymphomas were removed
and frozen in liquid nitrogen as a single-cell suspension for flow
cytometric analysis. Other tissues were also snap frozen for
comparative analysis.
Southern blot DNA analysis
Analysis of immunoglobin or T-cell receptor gene rearrangements
were used to determine thymic lymphoma clonal complexity. High-
molecular-weight DNA wasprepared fromthymic lymphocytes and
intact kidney using the Nucleon II kit (Scotlab). Restriction enzyme
digestion, agarose gel electrophoresis and DNA hybridization was
performed as previously described (Neil etal, 1984). Digested DNA
was transferred to Hybond N membranes (Amersham Intemational)
according to the manufacturer's protocol. Immunoglobulin gene
rearrangements were detected using a 1.7-kb BamHV/EcoRI frag-
mentJ11 fromtheIgheavy-chain locus Jcluster (Marcu etal, 1980).
TcR gene rearrangements were detected using a 496-bp polymerase
chain reaction (PCR)-generated fragment of theCo region derived
from a 1.2-kb fragment of clone 86T5 (Hendrick et al, 1984) or a
750-bp EcoRI/HindIII fragment of JP2 from the TcR c J locus
(Palacios and Samaridis, 1991). Probes were radiolabelled by
random priming using [a-32P]dCTP (3000 Ci mmol-1, Amersham
Intemational) to specific activities ofatleast 1 x 108 c.p.m. perjg of
DNA. Blots were washed to a final stringency of 0.1 x standard
saline citrate (SSC); 0.5% sodium dodecyl sulphate (SDS) at 60°C.
Monoclonal antibodies
The mouse IgGl F23.2 (anti-VP 8.2) and mouse IgG2a F23.1 (anti-
V,B 8.1,.2,.3) Ab (Kappler et al, 1988) were obtained from tissue
culture supematants (hybridomas kindlyprovided by DrP Marrack,
Howard Hughes Medical Institute, Co, USA) and purified by
protein A-Sepharose affinity chromatography. Biotinylation was
performed using biotin-N-hydroxysuccinimide according to manu-
facturers recommendations (Amersham Intemational). Biotinylated
Ab recognizing TcR V11, VP14 and V,8.1,.2 were purchased
from Pharminigen. All biotinylated Abs were visualized with strep-
tavidin-RED613 secondary reagent (Gibco BRL). Phenotypic char-
acterization was performed using anti-CD4-PE, anti-CD8-FITC
(Serotec, UK), anti-CD3e-Quantum Red (Sigma), anti-CD69-FITC
(Pharminigen) and anti-HSA-PE (Pharminigen). Total a/pTcR
expression was determined using an Ab that reacts with all oc[,TcR
(Kubo et al, 1989) conjugated to Quantum Red (Sigma).
Flow cytometric analysis of thymic lymphoma
lymphocytes
Single-cell suspensions were recovered from liquid nitrogen into
phosphate-buffered saline (PBS) containing 0.1% bovine serum
albumin (BSA) and 0.2% sodium azide and were distributed in
96-well round-bottom microplates (106 cells per well). Cells were
stained for 20 min at 4°C for each step in 100-gl volumes. For
four-colour analysis, cells were incubated first with 1 jg of
biotinylated mAbs recognizing TcR variable regions. The cells
were washed and incubated with streptavidin-RED613 then
sequentially exposed to optimal quantities ofanti-CD3s, anti-CD4
and anti-CD8 or to anti-pan TcRa/f, anti-HSA and anti-CD69. To
account for the possibility ofsteric hindrance affecting Ab binding
in four-colour analysis, single-stained controls were included for
each tumour analysed. Thymocytes and splenic lymphocytes
obtained from non-transgenic (B6/CBA x DBA/2)F, animals were
used as controls. Cells were analysed on an Epics Elite cytometer
(Coulter) using logarithmic scales for fluorescence data collection.
Viable cells were gated by a combination of forward light scatter
and 900 side scatter. A minimum of 10 000 tumour lymphocytes
and 20 000 control thymocytes were analysed. The proportion of
TcRVP8.3+ cells was indirectly determined by comparing binding
of anti-VP8.1,.2,.3 (F23.1) and anti-V,8.1,.2 Ab. Similarly, the
proportion of TcR V,8.1+ cells was determined by subtraction of
VP8.3+ and V038.2+ (F23.2) populations from the proportion of
V08.1,.2,.3+ cells (F23.1).
RESULTS
Biased usage of the V138.2 T-cell antigen receptor in
CD2 thymic lymphoma
The TcR repertoire in mice is strongly influenced by the products
ofendogenous mouse mammary tumour proviruses (MMTV; Mtv
loci). Thymocytes expressing TcR VP elements that are reactive
with MMTV-associated superantigens (SAg) undergo negative
selection, resulting in deletion of the vast majority ofcells; this is
reflected by the almost complete absence of these cells from the
peripheral T-cell population (Simpson et al, 1994). As (B6/CBA x
DBA/2)F1 mice carry numerous Mtv (Coligan et al, 1994), it was
expected that a large number ofTcRVP families would be deleted
(e.g.VP3, 5, 6,7, 8.1, 9, 11), whileVP8.2,VP8.3 andVP14 would
be among those spared (Coligan et al, 1994).
TheVP repertoire ofmyc-induced T-cell lymphomas was inves-
tigated by screening a cohort of 20 tumours arising in CD2-myc
transgenic mice on a B6/CBA x DBA/2 (F1) background. We have
previously reported that myc-induced thymic tumours can
comprise cells displaying a 'forbidden' VP phenotype (Cameron
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Figure 1 Flow cytometric evaluation of TcR V,B8.2 expression and DNA analyses of gene rearrangement in CD2-mycthymic lymphoma. The code name for each tumour is shown above. Corresponding kidney DNA (K) was analysed to indicate the position of the germline fragment (arrowed). EcoRI-or Hindlll- digested DNA was transferred to nylon filters by Southern blotting procedures and hybridized with [a-32P]dCTP-labelled Jil orJP2 probe, which detect 1g heavy- chain locus J cluster rearrangements or TcR P J locus rearrangements respectively. This analysis reveals clonal rearrangements with the loss of the germline fragment (arrowed) in some cases, indicating rearrangement of both alleles. Forflow cytometric analysis, total tumour lymphocytes were labelled with a panel of anti-TcR VPI Ab, as outlined in Materials and methods. Tumours expressing TcR V,B8.2 are shown with corresponding DNA analysis. Markers indicating positive fluorescence regions (gate J) were set according to negative control Ab staining (gate F)
et al, 1996). In order to further investigate these results, we exam-
ined these 20 tumours with monoclonal antibodies for T-cells
deleted on this background (VP8. 1 and ViI1) as well as T-cells for
non-deleting VP species (Vjl8.2, V,B8.3 and V0i14). One tumour
clone consisted of TcR Vii8.1+ cells, confirming our previous
observation that tumours bearing potentially autoreactive T-cell
receptors could arise in this system (data not included). However,
an unexpected finding was the high proportion of tumours (8 out
of 20) that contained substantial numbers of cells expressing
V,B8.2. No Vpll+, Vi8.3+ or VOW14 tumour populations were
detected and the remaining 11 tumours were uncharacterized with
thepanel ofTcRVP Ab used in this study.
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Figure 2 CD3, CD4 and CD8 surface antigen co-expression on TcR V,B8.2+ cells and TcR a/, expression on whole tumour lymphocytes. The code name for
each tumour is shown. Cells were labelled for TcR VP8.2 expression followed by CD3, CD4 and CD8 co-labelling. Cells expressing V,B8.2 were gated and
subsequent CD3, CD4 and CD8 expression analysed on these cells. Because of steric hindrance of TcR a/P Ab binding in the presence of V,B8.2 Ab, TcR a/P
expression was determined for the whole tumour cell population. The regions indicating the positively labelled cells were set in relation to isotype-matched
irrelevant negative controls labelled with the appropriate fluorochrome for each tumour. Regions indicated on CD3 and a/TcR histograms refer to high and low
levels of antigen density, which were determined using control thymocytes. Values for the percentage of positive cells are indicated
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Previous studies on the CD2-myc transgenic mice have shown
that tumours arising in these mice areusually clonal oroligoclonal.
To investigate the clonal complexity of the thymic tumours,
rearrangements of both the IgH locus and the TcR f gene were
determined (Figure 1 and results not shown). We have found that
non-productive IgH rearrangements, which are relatively frequent
(30-50%) in normal T-cell development (Born et al, 1988), are
useful markers of clonal identity in T-cell tumours (Blyth et al,
1995). As shown in Figure 1, rearrangement of one or both alleles
of the immunoglobulin heavy-chain gene was a frequent occur-
rence. In tumours in which IgH rearrangements were not present,
rearrangements of theJP2 orC1l locus were analysed (Figure 1).
As with previous results, this analysis revealed that CD2-myc
lymphomas were largely clonal and showed that the tissues
sampled were almost entirely composed of transformed cells. Six
of the eight V,B8.2+ tumours (4, 14, 19, 34, 43, 46) appeared to
represent single clones as defined by IgH or JP2 rearrangement
patterns. FurtherIgH rearrangementpatterns of tumours 33 and 42
suggest that these tumours were biclonal. This analysis was in
general supportedby theV,8.2+expressionprofiles as determined
by flow cytometry (Figure 1). The VP8.2+ expression profiles of
tumours 4, 14 and 19 are represented as singlepeaks in agreement
with theIgH Southern blot results. Tumour42 is clearlybiclonal as
definedbyIgH rearrangements butshows asingle stronglypositive
peak forVP8.2+expression, indicating that this tumour consists of
two VP8.2+ clones. The other biclonal tumour (33) shows both
VP8.2-positive and -negative clones. Although clonal by IgH
rearrangements, tumours 34, 43 and 46 are more heterogeneous in
their VP8.2 expression patterns. The reason for the disparity
between the apparentclonality, as defined by IgH rearrangements,
and the increasedheterogeneity ofVP8.2expression is not clear. It
is conceivable, however, that cell surface expression was down-
regulated on a proportion of the transformed thymocytes, perhaps
because sustainedexpression was notrequired for the late stages of
tumourgrowth.
In summary, this analysis indicates that the eight tumours were
composed of ten distinct clones of which nine could be classified
as VP8.2positive. Analysis ofIgH andJP2 rearrangements in the
remaining 12VP8.2-negative tumours revealed that these tumours
were composed of a total of 16 clones. Overall, therefore, the 20
tumours in the cohort were composed of 26 clones, of which one
expressed VP8.1 and nine expressed VP38.2 (35%). As it was
possible that thehighfrequency ofTcRVP8.2+tumour clones was
simply a reflection ofVP8.2 usage in normal untransformed T-cell
populations, we examined the representation of VP8.2+ cells in
both TcR oc/,+thymic populations and in Thyl.2+splenic popula-
tions fromnon-transgenic (DBA/2 xB6/CBA)F1 controls. In adult
thymus andspleen,V,38.2+cellsrepresented 16.5 ± 2.9% (n =6) of
aJ/4TcR+and 12.1 ± 1.5% (n = 5) ofThyl.2+populations respec-
tively. These data are of similar values to those obtained by others
(Kappler et al, 1988). When compared with the tumour cohort in
which 35% ofclones expressed TcRVP8.2, these data suggest that
the tumour VP repertoire was limited with an obvious skew
towards TcR V,8.2 usage.
TcR VP8.2+ populations in CD2-myc thymic lymphoma
resemble cells that have undergone or are undergoing
selection
CD3, CD4 and CD8 co-expression was determined on gated
V08.2+ clones to assess the developmental stage of these cells
(Figure 2). The majority (six out of nine) of VP8.2+ clones
comprised cells of a CD4-CD8+ phenotype with a high level of
CD3 expression (termed CD3+CD8 SP), suggesting that these
clones arose from cells that had completed positive selection.
TcR expression of the tumours was also determined using flow
cytometry, however double labelling with VP8.2 and a/, TcR Ab
resulted in reduced staining compared with single-stainedpositive
controls; as a result this analysis was carried out on whole tumour
populations. Although of lower intensity, TcR expression patterns
generally paralleled those ofCD3 with CD3+CD8 SP tumours 33,
4, 19 and 14 showing distinct single peaks of intermediate level
(Figure 2). As with the pattern ofVP8.2 expression in tumour 43,
CD3 and TcR levels are more heterogeneous in this tumour. The
CD3 expression pattern oftumour42reflects thebiclonal nature of
this tumour and suggests that one of the V,8.2+ clones is CD3hi
CD8+ while the other VJ38.2+ clone has lower levels of CD3.
Analysis ofTcR expression in this tumour also indicates that there
are two separate clones that differ in TcRintensity.
TcR V,8.2+ clones in tumours 46 and 34 contained significant
immature DPpopulations, whichexpressedcorrespondingly lower
levels of CD3 than seen in other V08.2+ tumour populations
(Figure 2). By contrast, the clones that did not express VP
elements recognized by the mAb panel were more heterogeneous
with respect to CD3, CD4 and CD8 expression (data not shown).
Fourteen of these clones were examined by flow cytometry; five
were composed primarily of CD3+CD8 SP cells while seven had
significant DPpopulations with varying levels ofCD3 expression.
Of the remainder, one clone was of a predominant CD3-CD8+ SP
phenotype and the other showed major subsets in both the
CD3+CD8 SP and CD3+DP compartments.
In addition to mature T-cell populations, CD8 SP cells are also
represented in the thymus as a transitional pre-double-positive
(DP) population. Such cells do not express detectable CD3 or
TcRcx chain, and CD8 antigen expression is defined as low
compared with antigen density on mature T-cells (Lucas et al,
1993; Anderson and Perlmutter, 1995). As six of the nine V,8.2+
clones show high levels of CD3 and CD8 expression levels
together with intermediate levels ofTcR, they appear to be repre-
sentative ofapost-selection population ratherthan thepre-double-
positive population of CD3-CD8'o cells. TcR V,B8.2+ clones in
tumours 46 and 34, and one of the two clones in tumour 42,
expressed low levels of a/, TcR, which was in agreement with the
predominant CD3IoDP immature phenotype.
While phenotypic analysis of tumours for CD3, CD4 and CD8
was indicative of a mature, post-selection T-cell phenotype, we
sought to define further the developmental compartment of these
cells using the conventional activation and maturation markers
CD69 and HSA (heat stable antigen) respectively. CD69 is an acti-
vation marker that is rapidly induced on mature peripheral T-cells
after stimulation through the TcR (Yamashita et al, 1993). CD69
has also been shown to be developmentally regulated in its expres-
sion on thymocytes. In particular, it is believed that CD69 identi-
fies a subpopulation ofthymocytes that are, or have recently been,
stimulated through their T-cell receptor complexes during positive
and negative selection (Yamashita et al, 1993). HSA characterizes
immature thymocytes from DN to early SP (Lucas et al, 1993,
1994). As shown in Figure 3, all V08.2+tumour clones exhibited
CD69 and HSA characteristics similar to those seen in V[i8.2+
cells undergoing normal thymocyte development in control mice.
For each clone, the majority of V08.2+ cells were of a HSA+
CD69-phenotype, with a small fraction of cells expressing CD69
British JournalofCancer(1997) 76(6), 739-746 . CancerResearch Campaign 1997744 G Webster etal
Control
K..
*,5 57.1111.5
I' 25.9 5.6
.,
CD69 1I
33
[--@ I ~76.3 20.3
)0 0.1 CD69 .1000
43
73.4|16.7 J 7 * 5.7
0.1 CD69 10m
46
eC
I
0
34
in Q F''1-im Ia
1000 0.1 C6 1000
Figure 3 Flow cytometric analysis of HSA and CD69 antigen expression on CD2-mycthymic lymphoma TcR V,8.2+ cells. Cells were labelled for TcR VJ38.2
expression, followed by co-labelling for HSA and CD69. Two-colour fluorescence dot plots represent CD69 and HSA expression on V,8.2+ cells. Control thymus
and tumour code names are indicated
with lower, down-regulated levels of HSA. Early SP cells
expressing HSA are localized in the thymic medulla where they
undergo further maturation leading ultimately to loss of HSA
expression on the majority of thymocytes (Scollay and Godfrey,
1995). This fact, considered with the HSA+CD3+ CD8 SP pheno-
type of the majority of tumours, indicates that these V,8.2+
tumour clones may have arisen from early medullary SP T-cells.
DISCUSSION
Antigen receptor-mediated selection has long been thought to play
a role in the growth of lymphoid malignancies (McGrath and
Weissman, 1979; McGrath et al, 1987) and to date there is accu-
mulating evidence that supports this hypothesis (Fulton et al, 1987,
Dighiero et al, 1991; Weissinger et al, 1991; Bahler and Levy,
1992; Cameron et al, 1996). This study was undertaken to further
elucidate the role for TcR signalling as a complementary, epige-
netic event in myc-induced thymic lymphoma in CD2-myc trans-
genic mice. Our analysis indicates a dominant non-random usage
ofpositively selected TcRVP8.2 in 35% oftumour clones (9 out of
26). Tumour TcR Vf8.2+ clones were characteristically mature
CD8 SP cells with only three ofthe nine Vj8.2+ clones comprising
significant DP populations and having correspondingly lower
levels of CD3. The shift towards the CD8 SP phenotype in these
tumours is somewhat surprising as the usual phenotype of CD2-
myc tumours is the DP stage. Accumulated data from a number of
different experiments involving large cohorts ofmice has revealed
that, overall, 70% ofCD2-myc-associated tumours are DP, whereas
only 20% are CD8 SP (Cameron et al, 1996 and unpublished
results). We have recently reported that a small number of tumours
arising in CD2-myc display a 'forbidden' VP phenotype. In agree-
ment with our previous findings, one tumour in the current study
British Journal of Cancer (1997) 76(6), 739-746
4
'Cl
co =
6ra
19
42
g*. g l..X * 71.3 22.4
8 F ~~~3.9t.4
NIS _ z .H_e '*.1 i * t *C**. 6 -
2
0 CancerResearch Campaign 1997Skewed V,B TcR expression in CD2-myc thymic lymphoma 745
expressed VP8.1, a potentially autoreactive TcR VP phenotype
(data not shown). It is worth noting that the tumours using
'forbidden' VP species are also significantly associated with the
CD8 SP phenotype (Cameron et al, 1996).
The intensity of CD3 and CD8 expression and the presence of
the maturation marker HSA on the majority oftumour thymocytes
strongly suggests that the VP8.2+ clones are derived from thymo-
cytes that were undergoing or that have undergone selection. The
restricted phenotype ofthese tumours and the involvement ofboth
positively and negatively selected TcRVP are in keeping with our
previous hypothesis that myc transformation is tightly associated
with the window of thymic development during which repertoire
selection occurs (Cameron et al, 1996).
These results suggest that selection events, mediated through
the TcR, may collaborate with myc during leukaemogenesis. The
exact nature of such interactions is less clear. It is possible that
initial transforming events occur at the DP stage and that, in a
proportion of tumours, TcR-specific interactions act both as a
contributing tumorigenic event and as a maturation signal. If
events analogous to positive selection are crucial for the survival
of preneoplastic lymphocytes, it might be expected that all T-cells
that are positively selected would be equally susceptible to trans-
formation. The skewed repertoire we have reported here indicates
that this is not the case, raising the possibility that the signals that
complement transformation in the VP8.2-expressing tumour
clones are qualitatively or quantitatively different.
One possibility is that interactions with superantigens and
normal MHC/peptide complexes may result in different outcomes.
Endogenous Mtv proviral sequences play an important role in
shaping the T-cell repertoire of mice via superantigen-mediated
negative selection of specific VP families. Until recently, there
were no reports of Mtv expression resulting in VP-specific posi-
tive selection. However, Scherer et al (1995) have shown that there
is a significant over-representation of Vf8.2+ CD4+ cells in mice
carrying Mtv 11, suggesting that this Mtv loci could positively
selectVP8.2+ thymocytes. Mtv 8 also led to an increase in VP8.2+
T-cells, although this increase was not significant. As the
mice used in our study were an F, offspring from DBA2 and
C57B16 x CBA\Ca mice, they harboured both Mtv 11 and Mtv 8.
Skewing of the tumour repertoire need not necessarily involve
endogenous or exogenous superantigen as it is clear that specific
micro-organisms and antigens preferentially use certain a/ TcR
combinations (for reviews see Nanda and Sercarz, 1993; Pannetier
et al, 1995) Furthermore, in mice that lack endogenous Mtv
sequences, CD4 and CD8 lymph node T-cells show marked differ-
ences in VP usage (Scherer et al, 1995). It is conceivable that
emerging tumour clones expressing VP8.2 are supported by a
widely expressed and/or abundant conventional antigen in the
thymus. In support of this notion, a number of recent studies
suggest that antigen-driven proliferation of early SP cells does
occur to some extent in normal thymus medulla (reviewed by
Scollay and Godfrey, 1995).
Differences between the VP repertoire of normally selected
thymocytes and tumours emerging from this population strongly
suggest that TcR-mediated signals complement myc activation in
the development ofthymic lymphoma. From these studies, it is not
possible to determine whether the TcR is important for establish-
ment of the tumour alone or whether it is required for sustained
clonal outgrowth. Further studies will focus on the functional
importance of the TcR on tumour growth and the nature of the
antigen(s) involved.
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